Philadelphie chromosome—Positive <i>de novo</i>acute myeloid leukemia. Isolated meningeal relapse in a patient treated with imatinib mesylate

作     者：I. Ben Amor S. Hdiji Mseddi O. Kassar S. Hdiji Mnif Ines Jdidi M. Mdhaffar L. Kammoun H. Bellaaj A. Saad M. Elloumi 

作者机构：Cytogenetics Laboratory Farhat Hached Hospital Sousse Tunisia Hematology department Hedi Chaker Hospital Sfax Tunisia Hematology department Hedi Chaker Hospital Sfax Tunisia Hematology Laboratory Habib Bourguiba Hospital Sfax Tunisia Molecular Biology Unit Institue Pasteur Tunis Tunisia 

出 版 物：《Case Reports in Clinical Medicine》 (临床医学病理报告（英文）)

年 卷 期：2013年第2卷第2期

页      面：167-169页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Acute Myeloid Leukemia Philadelphie Chromosome Meningeal Relapse 

摘      要：Acute myeloid leukemia philadelphie positive (Ph+ AML) is a rare aggressive acute leukemia with poor prognosis. We report a patient with ph positive AML (FAB5), the transcript bcr/abl was not performed at diagnosis. She achieved complete remission after conventional induction chemotherapy. The consolidation therapy was based on Imatinib only due to infectious complications. She was in complete hematologic and cytogenetic remission for 19 months, and after she exhibited an isolated meningeal relapse. A second remission was achieved with intrathecal chemotherapy and cranial irradiation. Imatinib was switched to second generation Tyrosine kinase Inhibitor which had better diffusion into cerebrospinal fluid. She is in complete hematologic, cytogenetic and meningeal remission after 14 months of treatment. Imatinib monotherapy affords insufficient protection from CNS relapse. Second generation Tyrosine kinase Inhibitor seems to have better efficiency. Ph+ AML with monoblastic differentiation should be considered, like Ph+ ALL, at high risk of meningeal leukemia and should receive central nervous system prophylaxis.